Drugs / DM005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06515990 | Oct 2024 → Oct 2026 expected | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Doma Biopharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DM005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515990 ↗ |
| Route | Intravenous | “An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.” NCT06515990 ↗ |
| Target | EGFR | “DM005, a bispecific ADC developed using fully human antibodies with a common light chain, which targets c-MET and EGFR.” NCT06515990 ↗ |
| Target | MET | “DM005, a bispecific ADC developed using fully human antibodies with a common light chain, which targets c-MET and EGFR.” NCT06515990 ↗ |